Clinical trial · Interventional
Comparison of SBRTand Repeat TACE for HCC
Comparison of Stereotactic Body Radiation Therapy (SBRT)and Repeat Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma (HCC) as a Local Salvage Treatment After Incomplete TACE : A Prospective Randomized Trial
NCT03326375CI-TRIAL-00030142STHunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comparison of Stereotactic Body Radiation Therapy (SBRT) and repeated transarterial chemoembolization (TACE) for Hepatocellular Carcinoma (HCC)as a Local Salvage Treatment after first incomplete TACE
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HepatoCellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SBRT | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- SBRT (Stereotatic body radiotherapy)
- description
- Treatment of SBRT in HCC patients who have incomplete response after first TACE
- interventionNames
- Radiation: SBRT
- type
- NO_INTERVENTION
- label
- TACE (Transarterial chemoembolization)
- description
- Treatment of repeated TACE in HCC patients who have incomplete response after first TACE
Primary outcomes (1)
- measure
- Local tumor control (efficacy fo SBRT)
- timeFrame
- 1 year
- description
- To evaluate the effect of SBRT. Local tumor control is defined as the disappearance of any intraarterial enhancement in all target lesions. Local tumor control will be measured on triphasic Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI). Patient will be asked to visit their study doctor for follow-up exams and imaging (CT or MRI) every 3 months.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Age \>18 years * Eastern cooperative oncology group(ECOG) score 0 to 2 * Primary HCC * HCC (single nodule ≤ 7 cm or max 3 nodules ≤ 3 cm) * Child-Turgottei-Pugh A or B * Unresectable lesion or medically contraindicated surgery or a case in which surgery was declined. * No evidence of radiologically definable major vascular invasion or extrahepatic disease * Previously incomplete TACE with radiologically defined residual disease after first TACE * Informed consent Exclusion Criteria: * Prior TACE to the target lesion * Contraindication to receiving radiotherapy or TACE * Decompensated liver cirrhosis * Extrahepatic mets * Pregnancy * Patients with other cancers
References
Publications (0)
Data not yet available
No reference posted for this study.